CD44 | CD44 molecule (Indian blood group) | Blood group antigen proteins Cancer-related genes CD markers FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
CD80 | CD80 molecule | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD86 | CD86 molecule | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Mixed |
CES1 | Carboxylesterase 1 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Expressed in all |
CFTR | Cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CHD1 | Chromodomain helicase DNA binding protein 1 | Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
CHRM1 | Cholinergic receptor, muscarinic 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
CHRM3 | Cholinergic receptor, muscarinic 3 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
CHRNA7 | Cholinergic receptor, nicotinic, alpha 7 (neuronal) | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Mixed |
CKB | Creatine kinase, brain | Cancer-related genes Candidate cardiovascular disease genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
CKM | Creatine kinase, muscle | Candidate cardiovascular disease genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
CLCN2 | Chloride channel, voltage-sensitive 2 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Mixed |
COMT | Catechol-O-methyltransferase | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
CPS1 | Carbamoyl-phosphate synthase 1, mitochondrial | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins
| | | | | Group enriched |
CPT1A | Carnitine palmitoyltransferase 1A (liver) | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
CPT2 | Carnitine palmitoyltransferase 2 | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
CSF3R | Colony stimulating factor 3 receptor (granulocyte) | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CYP11B1 | Cytochrome P450, family 11, subfamily B, polypeptide 1 | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted intracellular proteins
| | | | | Tissue enriched |
CYP17A1 | Cytochrome P450, family 17, subfamily A, polypeptide 1 | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
CYP19A1 | Cytochrome P450, family 19, subfamily A, polypeptide 1 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enriched |
CYP51A1 | Cytochrome P450, family 51, subfamily A, polypeptide 1 | Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
DBH | Dopamine beta-hydroxylase (dopamine beta-monooxygenase) | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enriched |
DDC | Dopa decarboxylase (aromatic L-amino acid decarboxylase) | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Tissue enhanced |
DHODH | Dihydroorotate dehydrogenase (quinone) | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
DNMT1 | DNA (cytosine-5-)-methyltransferase 1 | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Transcription factors
| | | | | Expressed in all |
DPEP1 | Dipeptidase 1 (renal) | Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
DPP4 | Dipeptidyl-peptidase 4 | CD markers Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
DRD5 | Dopamine receptor D5 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
EDNRA | Endothelin receptor type A | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
EGFR | Epidermal growth factor receptor | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
ELANE | Elastase, neutrophil expressed | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
EPHA2 | EPH receptor A2 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins RAS pathway related proteins
| | | | | Tissue enhanced |
ERBB2 | V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
ESR1 | Estrogen receptor 1 | Cancer-related genes Disease related genes FDA approved drug targets Nuclear receptors Predicted intracellular proteins Transcription factors
| | | | | Group enriched |
F2 | Coagulation factor II (thrombin) | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enriched |
F8 | Coagulation factor VIII, procoagulant component | Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Expressed in all |
FASN | Fatty acid synthase | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
FCER1A | Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide | FDA approved drug targets Predicted membrane proteins
| | | | | Mixed |
FCER1G | Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide | FDA approved drug targets Predicted membrane proteins
| | | | | Expressed in all |
FCGR2A | Fc fragment of IgG, low affinity IIa, receptor (CD32) | CD markers FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
FCGR2B | Fc fragment of IgG, low affinity IIb, receptor (CD32) | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |
FCGR3A | Fc fragment of IgG, low affinity IIIa, receptor (CD16a) | CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
FDPS | Farnesyl diphosphate synthase | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
FGA | Fibrinogen alpha chain | Cancer-related genes Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
FGF1 | Fibroblast growth factor 1 (acidic) | Cancer-related genes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | | | Group enriched |
FGF2 | Fibroblast growth factor 2 (basic) | Cancer-related genes Candidate cardiovascular disease genes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | | | Mixed |
FGFR2 | Fibroblast growth factor receptor 2 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
FLT1 | Fms-related tyrosine kinase 1 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enriched |
FLT4 | Fms-related tyrosine kinase 4 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
FN1 | Fibronectin 1 | Cancer-related genes Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |